Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
Get Alerts ALNY Hot Sheet
Price: $144.41 -0.52%
Revenue Growth %: +33.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +33.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.21), $0.16 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.75 million.
At March 31, 2016, Alnylam had cash, cash equivalents and total marketable securities of $1.21 billion, as compared to $1.28 billion at December 31, 2015. In April 2016, the company entered into credit agreements described below with proceeds of $150.0 million of restricted marketable securities
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Acme United (ACU) Misses Q1 EPS by 20c
- Wipro (WIT) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!